Shield Therapeutics plc

LSE STX.L

Shield Therapeutics plc Capital Expenditure for the year ending December 31, 2023: USD -3.75 M

Shield Therapeutics plc Capital Expenditure is USD -3.75 M for the year ending December 31, 2023, a -63.77% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Shield Therapeutics plc Capital Expenditure for the year ending December 31, 2022 was USD -2.29 M, a 18.00% change year over year.
Shield Therapeutics plc Capital Expenditure for the year ending December 31, 2021 was USD -2.79 M, a -8,792.56% change year over year.
Shield Therapeutics plc Capital Expenditure for the year ending December 31, 2020 was USD -31.41 K, a 98.29% change year over year.
Shield Therapeutics plc Capital Expenditure for the year ending December 31, 2019 was USD -1.83 M, a 56.96% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

LSE: STX.L

Shield Therapeutics plc

CEO	Mr. Anders Lundstrom
IPO Date	Feb. 26, 2016
Location	United Kingdom
Headquarters	Northern Design Centre
Employees	73
Sector	Health Care
Industries Pharmaceuticals

Description

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.

Key trends

Past 5 years